{"id":"flumedroxone-acetate","rwe":[{"pmid":"716957","year":"1978","title":"Solubilization of spironolactone and flumedroxone acetate.","finding":"","journal":"Acta pharmaceutica Suecica","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"demigran","offLabel":[],"synonyms":["flumedroxone acetate","demigran","demigrana","leomigran","flumedrossone"],"timeline":[],"approvals":[],"brandName":"Demigran","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Unfortunately, we don't have enough information to explain how Demigran works in simple terms. However, in general, small molecule drugs like Demigran work by interacting with specific proteins or receptors in the body to produce a desired effect. This interaction can either block or enhance the normal function of these proteins, leading to changes in the body's chemistry and ultimately, the desired therapeutic effect.","oneSentence":"Demigran works by binding to a specific target, but the exact mechanism is unclear.","technicalDetail":"Demigran's mechanism of action is not well understood, but it is likely to involve binding to a specific target protein, potentially altering its activity or expression. This could lead to changes in downstream signaling pathways, influencing various cellular processes and ultimately contributing to its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3749","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=flumedroxone acetate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:33:23.313721","biosimilars":[],"competitors":[],"genericName":"flumedroxone acetate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"S0S93EK936","CHEBI":"CHEBI:135717","INN_ID":"2035","UMLSCUI":"C0117901","DRUGBANK_ID":"DB13610","PUBCHEM_CID":"192154","MESH_SUPPLEMENTAL_RECORD_UI":"C007732"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1978","pmid":"716957","title":"Solubilization of spironolactone and flumedroxone acetate.","journal":"Acta pharmaceutica Suecica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Demigran (flumedroxone acetate) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for Demigran are also unknown. Further information on its pharmacokinetics, such as half-life and bioavailability, is not available. As a result, key safety considerations and generic manufacturers are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}